Skip to main content

Panic Disorder

11
Pipeline Programs
14
Companies
20
Clinical Trials
1 recruiting
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
3
1
2
5
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

14 companies ranked by most advanced pipeline stage

Pfizer
PfizerNEW YORK, NY
6 programs
2
2
Sertraline and Alprazolam XRPhase 41 trial
alprazolam XRPhase 41 trial
Venlafaxine ERPhase 31 trial
Venlafaxine ERPhase 31 trial
Sertraline hydrochlorideN/A1 trial
+1 more programs
Active Trials
NCT00605917Completed997Est. Sep 2011
NCT00605865Completed2,272Est. Sep 2011
NCT00038896Completed343Est. Dec 2002
+3 more trials
ViiV Healthcare
ViiV HealthcareNC - Durham
3 programs
1
Paroxetine CRPhase 4
ParoxetineN/A
ParoxetineN/A
Prevail Therapeutics
1 program
1
DuloxetinePhase 41 trial
Active Trials
NCT00438971Completed15Est. Jan 2009
Lundbeck
LundbeckDenmark - Copenhagen
1 program
1
LexaproPhase 41 trial
Active Trials
NCT00767871Completed46Est. Dec 2008
Nobilis Therapeutics
1 program
1
XenonPhase 2/31 trial
Active Trials
NCT04432155Unknown200Est. Dec 2021
MSD
MSDIreland - Ballydine
1 program
1
Cognitive-behavioral therapyPhase 21 trial
Active Trials
NCT00725725Terminated46Est. Apr 2010
Sharp Therapeutics
Sharp TherapeuticsPA - Pittsburgh
1 program
1
Cognitive-behavioral therapyPhase 2
AbbVie
AbbVieNORTH CHICAGO, IL
1 program
1
DarigabatPhase 21 trial
Active Trials
NCT05941442Completed80Est. Mar 2025
GSK
GSKLONDON, United Kingdom
3 programs
ParoxetineN/A1 trial
ParoxetineN/A1 trial
Paroxetine CRPHASE_41 trial
Active Trials
NCT01376128Completed96Est. May 2009
NCT01371474Completed1,483Est. Jun 2008
NCT00492414Unknown
Jerusalem Pharmaceuticals
Jerusalem PharmaceuticalsIsrael - Ramallah
2 programs
CBT- both internet and face to faceN/A1 trial
ICBT for panic and depressionN/A1 trial
Active Trials
NCT04029740Unknown80Est. Dec 2021
NCT04659577Completed130Est. Jan 2022
Linnaeus Therapeutics
Linnaeus TherapeuticsNJ - Haddonfield
1 program
Brief interventionsN/A1 trial
Active Trials
NCT04900064Recruiting1,242Est. Dec 2026
Relief Therapeutics
Relief TherapeuticsSwitzerland - Geneva
1 program
Group self-management support program for anxiety disordersN/A1 trial
Active Trials
NCT05124639Active Not Recruiting414Est. Dec 2026
Integrated Biosciences
Integrated BiosciencesCA - San Carlos
1 program
Transdiagnostic Cognitive-Behavioral TherapyN/A1 trial
Active Trials
NCT02811458Completed231Est. Jul 2019
UCB Pharma
UCB PharmaBelgium - Brussels
1 program
levetiracetamPHASE_31 trial
Active Trials
NCT00279617Completed15Est. Mar 2009

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
LundbeckLexapro
Prevail TherapeuticsDuloxetine
Pfizeralprazolam XR
PfizerSertraline and Alprazolam XR
UCB Pharmalevetiracetam
PfizerVenlafaxine ER
PfizerVenlafaxine ER
Nobilis TherapeuticsXenon
AbbVieDarigabat
MSDCognitive-behavioral therapy
Relief TherapeuticsGroup self-management support program for anxiety disorders
Linnaeus TherapeuticsBrief interventions
Jerusalem PharmaceuticalsCBT- both internet and face to face
Jerusalem PharmaceuticalsICBT for panic and depression
Integrated BiosciencesTransdiagnostic Cognitive-Behavioral Therapy

Showing 15 of 19 trials with date data

Clinical Trials (20)

Total enrollment: 8,542 patients across 20 trials

NCT00492414GSKParoxetine CR

Costs of Lost Productive Time Among Korean Workers With Panic Disorder and Effect of Treatment With Paroxetine Controlled Release

Phase 4Unknown
NCT00767871LundbeckLexapro

Changes of Cerebral Glucose Metabolism and After 12 Weeks of Escitalpram Treatment in Panic Disorder

Start: Mar 2007Est. completion: Dec 200846 patients
Phase 4Completed
NCT00438971Prevail TherapeuticsDuloxetine

The Efficacy and Tolerability of Duloxetine for the Treatment of Panic Disorder

Start: Aug 2006Est. completion: Jan 200915 patients
Phase 4Completed
NCT00634790Pfizeralprazolam XR

A Study To Assess the Safety of Extended Release Alprazolam for the Treatment of Adolescents With Panic Disorder or Anxiety With Panic Attacks

Start: May 2004Est. completion: Oct 200449 patients
Phase 4Terminated
NCT00198094PfizerSertraline and Alprazolam XR

A Study of Sertraline and Early Alprazolam XR Administration Versus Sertraline Only in Panic Disorder Patients

Start: Dec 2003Est. completion: Sep 2007150 patients
Phase 4Completed
NCT00279617UCB Pharmalevetiracetam

Levetiracetam Treatment of Panic Disorder and Lactate-Induced Panic Attacks

Start: Jan 2006Est. completion: Mar 200915 patients
Phase 3Completed
NCT00044772PfizerVenlafaxine ER

Study Evaluating Venlafaxine ER in Patients With Panic Disorder

Start: Nov 2001Est. completion: Apr 2003653 patients
Phase 3Completed
NCT00038896PfizerVenlafaxine ER

Study Evaluating Venlafaxine ER in Adults With Panic Disorder

Start: Apr 2001Est. completion: Dec 2002343 patients
Phase 3Completed
NCT04432155Nobilis TherapeuticsXenon

Xenon Inhalation for Treatment of Panic Disorder

Start: Jun 2021Est. completion: Dec 2021200 patients
Phase 2/3Unknown
NCT05941442AbbVieDarigabat

A Study to Evaluate Efficacy, Safety, and Tolerability of Darigabat in Participants With Panic Disorder

Start: Jul 2023Est. completion: Mar 202580 patients
Phase 2Completed
NCT00725725MSDCognitive-behavioral therapy

Org 25935 Versus Placebo as Augmentation to Cognitive-behavioral Therapy to Treat Panic Disorder (P05705)

Start: Jul 2008Est. completion: Apr 201046 patients
Phase 2Terminated
NCT05124639Relief TherapeuticsGroup self-management support program for anxiety disorders

Clinical Trial of a Group Self-management Support Program for Anxiety Disorders

Start: Oct 2022Est. completion: Dec 2026414 patients
N/AActive Not Recruiting
NCT04900064Linnaeus TherapeuticsBrief interventions

Evaluation of Primary Care Behavioral Health (PCBH) With the Addition of Self-help CBT - A Randomized Multicenter Trial

Start: Jun 2021Est. completion: Dec 20261,242 patients
N/ARecruiting
NCT04029740Jerusalem PharmaceuticalsCBT- both internet and face to face

Exosomal microRNAs as a Biomarker in Panic Disorder and in Response to CBT

Start: Mar 2019Est. completion: Dec 202180 patients
N/AUnknown
NCT04659577Jerusalem PharmaceuticalsICBT for panic and depression

Attitudes of Professionals and the General Public in Israel Regarding ICBT

Start: Nov 2016Est. completion: Jan 2022130 patients
N/ACompleted
NCT02811458Integrated BiosciencesTransdiagnostic Cognitive-Behavioral Therapy

Clinical Trial of Transdiagnostic Cognitive-Behavior Therapy for Anxiety Disorders

Start: Sep 2016Est. completion: Jul 2019231 patients
N/ACompleted
NCT01376128GSKParoxetine

Special Drug Use Investigation for PAXIL Tablet (Pediatric Panic Disorder)

Start: Mar 2008Est. completion: May 200996 patients
N/ACompleted
NCT00605917PfizerSertraline hydrochloride

Special Investigation Of J Zoloft For Panic Disorder Patients

Start: Apr 2007Est. completion: Sep 2011997 patients
N/ACompleted
NCT00605865PfizerSertraline hydrochloride

Drug Use Investigation of Jzoloft.

Start: Apr 2007Est. completion: Sep 20112,272 patients
N/ACompleted
NCT01371474GSKParoxetine

Special Drug Use Investigation for PAXIL Tablet (Investigation in Case of Administered From 20mg/Day)

Start: Apr 2006Est. completion: Jun 20081,483 patients
N/ACompleted

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

2 late-stage (Phase 3) programs, potential near-term approvals
1 actively recruiting trials targeting 8,542 patients
14 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.